Now showing items 1-20 of 38

    • 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. 

      Peck, B; Bland, P; Mavrommati, I; Muirhead, G; Cottom, H; Wai, PT; Maguire, SL; Barker, HE; Morrison, E; Kriplani, D; Yu, L; Gibson, A; Falgari, G; Brennan, K; Farnie, G; Buus, R; Marlow, R; Novo, D; Knight, E; Guppy, N; Kolarevic, D; Susnjar, S; Milijic, NM; Naidoo, K; Gazinska, P; Roxanis, I; Pancholi, S; Martin, L-A; Holgersen, EM; Cheang, MCU; Noor, F; Postel-Vinay, S; Quinn, G; McDade, S; Krasny, L; Huang, P; Daley, F; Wallberg, F; Choudhary, JS; Haider, S; Tutt, AN; Natrajan, R (2021-01-28)
      Triple-negative breast cancers (TNBC) are resistant to standard-of-care chemotherapy and lack known targetable driver gene alterations. Identification of novel drivers could aid the discovery of new treatment strategies ...
    • Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer. 

      Tutt, ANJ; Garber, JE; Kaufman, B; Viale, G; Fumagalli, D; Rastogi, P; Gelber, RD; de Azambuja, E; Fielding, A; Balmaña, J; Domchek, SM; Gelmon, KA; Hollingsworth, SJ; Korde, LA; Linderholm, B; Bandos, H; Senkus, E; Suga, JM; Shao, Z; Pippas, AW; Nowecki, Z; Huzarski, T; Ganz, PA; Lucas, PC; Baker, N; Loibl, S; McConnell, R; Piccart, M; Schmutzler, R; Steger, GG; Costantino, JP; Arahmani, A; Wolmark, N; McFadden, E; Karantza, V; Lakhani, SR; Yothers, G; Campbell, C; Geyer, CE; OlympiA Clinical Trial Steering Committee and Investigators (2021-06-03)
      <h4>Background</h4>Poly(adenosine diphosphate-ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients ...
    • AllergoOncology: Expression platform development and functional profiling of an anti-HER2 IgE antibody. 

      Ilieva, KM; Fazekas-Singer, J; Bax, HJ; Crescioli, S; Montero-Morales, L; Mele, S; Sow, HS; Stavraka, C; Josephs, DH; Spicer, JF; Steinkellner, H; Jensen-Jarolim, E; Tutt, ANJ; Karagiannis, SN (2019-10)
    • Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial. 

      Sipos, O; Tovey, H; Quist, J; Haider, S; Nowinski, S; Gazinska, P; Kernaghan, S; Toms, C; Maguire, S; Orr, N; Linn, SC; Owen, J; Gillett, C; Pinder, SE; Bliss, JM; Tutt, A; Cheang, MCU; Grigoriadis, A (2021-01)
      <h4>Background</h4>In the TNT trial of triple negative breast cancer (NCT00532727), germline BRCA1/2 mutations were present in 28% of carboplatin responders. We assessed quantitative measures of structural chromosomal ...
    • Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. 

      Tutt, A; Tovey, H; Cheang, MCU; Kernaghan, S; Kilburn, L; Gazinska, P; Owen, J; Abraham, J; Barrett, S; Barrett-Lee, P; Brown, R; Chan, S; Dowsett, M; Flanagan, JM; Fox, L; Grigoriadis, A; Gutin, A; Harper-Wynne, C; Hatton, MQ; Hoadley, KA; Parikh, J; Parker, P; Perou, CM; Roylance, R; Shah, V; Shaw, A; Smith, IE; Timms, KM; Wardley, AM; Wilson, G; Gillett, C; Lanchbury, JS; Ashworth, A; Rahman, N; Harries, M; Ellis, P; Pinder, SE; Bliss, JM (2018-05)
      Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also repairs ...
    • Controversial issues in the neoadjuvant treatment of triple-negative breast cancer. 

      Fitzpatrick, A; Tutt, A (2019-01)
      Triple-negative breast cancer (TNBC), as a collective group of heterogenous tumours, displays the highest rate of distant recurrence and lowest survival from metastatic disease across breast cancer subtypes. However, a ...
    • Crosstalk between Innate Lymphoid Cells and Other Immune Cells in the Tumor Microenvironment 

      Flores-Borja, F; Irshad, S; Gordon, P; Wong, F; Sheriff, I; Tutt, A; Ng, T (HINDAWI LTD, 2016-01-01)
    • A decade of clinical development of PARP inhibitors in perspective. 

      Mateo, J; Lord, CJ; Serra, V; Tutt, A; Balmaña, J; Castroviejo-Bermejo, M; Cruz, C; Oaknin, A; Kaye, SB; de Bono, JS (2019-09)
      Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair capacities in tumour cells. DNA damage repair defects are common in different cancer types; these alterations can also induce ...
    • Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer. 

      Natrajan, R; Tutt, ANJ; Lord, CJ (2018-03)
      <b/> Two reports in this issue of Cancer Discovery outline how the genomic composition of tumors, including the presence of intragenic gene fusions, could inform the selection of treatment approaches in aggressive forms ...
    • E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. 

      Bajrami, I; Marlow, R; van de Ven, M; Brough, R; Pemberton, HN; Frankum, J; Song, F; Rafiq, R; Konde, A; Krastev, DB; Menon, M; Campbell, J; Gulati, A; Kumar, R; Pettitt, SJ; Gurden, MD; Cardenosa, ML; Chong, I; Gazinska, P; Wallberg, F; Sawyer, EJ; Martin, L-A; Dowsett, M; Linardopoulos, S; Natrajan, R; Ryan, CJ; Derksen, PWB; Jonkers, J; Tutt, ANJ; Ashworth, A; Lord, CJ (2018-04)
      The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumors. Precision medicine approaches that exploit this characteristic are not available. Using perturbation screens in breast tumor cells ...
    • Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer. 

      Naidoo, K; Wai, PT; Maguire, SL; Daley, F; Haider, S; Kriplani, D; Campbell, J; Mirza, H; Grigoriadis, A; Tutt, A; Moseley, PM; Abdel-Fatah, TMA; Chan, SYT; Madhusudan, S; Rhaka, EA; Ellis, IO; Lord, CJ; Yuan, Y; Green, AR; Natrajan, R (2018-01)
      Disruption of Cyclin-Dependent Kinase 12 (<i>CDK12</i>) is known to lead to defects in DNA repair and sensitivity to platinum salts and PARP1/2 inhibitors. However, <i>CDK12</i> has also been proposed as an oncogene in ...
    • A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics. 

      Quist, J; Mirza, H; Cheang, MCU; Telli, ML; O'Shaughnessy, JA; Lord, CJ; Tutt, ANJ; Grigoriadis, A (2019-01)
      The molecular complexity of triple-negative breast cancers (TNBCs) provides a challenge for patient management. We set out to characterize this heterogeneous disease by combining transcriptomics and genomics data, with the ...
    • Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study. 

      Lawler, K; Papouli, E; Naceur-Lombardelli, C; Mera, A; Ougham, K; Tutt, A; Kimbung, S; Hedenfalk, I; Zhan, J; Zhang, H; Buus, R; Dowsett, M; Ng, T; Pinder, SE; Parker, P; Holmberg, L; Gillett, CE; Grigoriadis, A; Purushotham, A (2017-10-13)
      Metastases from primary breast cancers can involve single or multiple organs at metastatic disease diagnosis. Molecular risk factors for particular patterns of metastastic spread in a clinical population are limited.A ...
    • Genomic Evolution of Breast Cancer Metastasis and Relapse. 

      Yates, LR; Knappskog, S; Wedge, D; Farmery, JHR; Gonzalez, S; Martincorena, I; Alexandrov, LB; Van Loo, P; Haugland, HK; Lilleng, PK; Gundem, G; Gerstung, M; Pappaemmanuil, E; Gazinska, P; Bhosle, SG; Jones, D; Raine, K; Mudie, L; Latimer, C; Sawyer, E; Desmedt, C; Sotiriou, C; Stratton, MR; Sieuwerts, AM; Lynch, AG; Martens, JW; Richardson, AL; Tutt, A; Lønning, PE; Campbell, PJ (2017-08)
      Patterns of genomic evolution between primary and metastatic breast cancer have not been studied in large numbers, despite patients with metastatic breast cancer having dismal survival. We sequenced whole genomes or a panel ...
    • Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node-positive breast cancers. 

      Grigoriadis, A; Gazinska, P; Pai, T; Irhsad, S; Wu, Y; Millis, R; Naidoo, K; Owen, J; Gillett, CE; Tutt, A; Coolen, AC; Pinder, SE (2018-01-08)
      The prognostic importance of lymph node (LN) status and tumour-infiltrating lymphocytes (TILs), is well established, particularly TILs in triple negative breast cancers (TNBCs). So far, few studies have interrogated changes ...
    • Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. 

      Chopra, N; Tovey, H; Pearson, A; Cutts, R; Toms, C; Proszek, P; Hubank, M; Dowsett, M; Dodson, A; Daley, F; Kriplani, D; Gevensleben, H; Davies, HR; Degasperi, A; Roylance, R; Chan, S; Tutt, A; Skene, A; Evans, A; Bliss, JM; Nik-Zainal, S; Turner, NC (2020-05-29)
      Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harboring evidence of defective homologous recombination (HR) DNA repair. Here, within a phase 2 window clinical trial, RIO ...
    • HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. 

      Davies, H; Glodzik, D; Morganella, S; Yates, LR; Staaf, J; Zou, X; Ramakrishna, M; Martin, S; Boyault, S; Sieuwerts, AM; Simpson, PT; King, TA; Raine, K; Eyfjord, JE; Kong, G; Borg, Å; Birney, E; Stunnenberg, HG; van de Vijver, MJ; Børresen-Dale, A-L; Martens, JWM; Span, PN; Lakhani, SR; Vincent-Salomon, A; Sotiriou, C; Tutt, A; Thompson, AM; Van Laere, S; Richardson, AL; Viari, A; Campbell, PJ; Stratton, MR; Nik-Zainal, S (2017-04)
      Approximately 1-5% of breast cancers are attributed to inherited mutations in BRCA1 or BRCA2 and are selectively sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. In other cancer types, germline and/or somatic ...
    • Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer. 

      Patel, N; Weekes, D; Drosopoulos, K; Gazinska, P; Noel, E; Rashid, M; Mirza, H; Quist, J; Brasó-Maristany, F; Mathew, S; Ferro, R; Pereira, AM; Prince, C; Noor, F; Francesch-Domenech, E; Marlow, R; de Rinaldis, E; Grigoriadis, A; Linardopoulos, S; Marra, P; Tutt, ANJ (2018-03-13)
      Triple negative breast cancers (TNBCs) lack recurrent targetable driver mutations but demonstrate frequent copy number aberrations (CNAs). Here, we describe an integrative genomic and RNAi-based approach that identifies ...
    • Integrin-Mediated Macrophage Adhesion Promotes Lymphovascular Dissemination in Breast Cancer. 

      Evans, R; Flores-Borja, F; Nassiri, S; Miranda, E; Lawler, K; Grigoriadis, A; Monypenny, J; Gillet, C; Owen, J; Gordon, P; Male, V; Cheung, A; Noor, F; Barber, P; Marlow, R; Francesch-Domenech, E; Fruhwirth, G; Squadrito, M; Vojnovic, B; Tutt, A; Festy, F; De Palma, M; Ng, T (2019-05)
      Lymphatic vasculature is crucial for metastasis in triple-negative breast cancer (TNBC); however, cellular and molecular drivers controlling lymphovascular metastasis are poorly understood. We define a macrophage-dependent ...